AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01868412 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Activon Tube 25 g
Description: Wound care with the medical honey is carried out in the same manner than the resin salve treatment: honey may be spread directly onto the wound and the wound area is covered with a bandage suitable for local wound care. Similarly, if the skin condition is more widespread or wound contains cavities or fistulae, the medical honey may be spread as a film with a thickness of at least 1 mm onto a gauze or gauze ribbon that is then used to fill the cavity or fistulae channel. Bandages are changed every 1-3 days, depending on the severity of infection and amount of wound secretion.
Study NCT00104884 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Depsipeptide
Description: Given IV
Study NCT02806661 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vagus nerve-preserving Robot-assisted Gastrectomy
Study NCT02806661 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Robot-assisted Gastrectomy
Study NCT03715907 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial Incentives
Description: Incentives for gap closure.
Study NCT03715907 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Information
Description: Information on care gap and closure process.
Study NCT02294864 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Percutaneous Pulsed Radiofrequency
Description: Pulsed Radiofrequency
Study NCT02294864 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Physical Therapy
Study NCT04831346 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low level laser
Description: 940 nm wavelength with 0.2 W output power and 2 J energy applied for 10 seconds with an energy density of 2.5 J/cm2.
Study NCT04831346 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Soft occlusive splint
Description: A vacuum-formed soft occlusal splint made from a 2-mm-thick elastic rubber sheets.~Participants are instructed to always wear the splint except during mealtimes and oral hygiene.
Study NCT03298737 — intervention group
Intervention type: BEHAVIORAL
Intervention: Covert Spatial Attention
Description: During behavioral sessions, subjects will sit in a dark room and view a video monitor placed at the minimum of 57 cm distance away from the subject. Staff will be present throughout all the testing to assist the subject and monitor equipment that is used for tracking their eye position. Subjects will be asked to maintain their heads in a stable position of rest in order to insure accurate tracking of their eye position. To stabilize their head, subjects will either use a chin rest in which they position their chin on a soft pad mounted in front of a video screen, or they may use a bite bar.
Study NCT03740113 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Kids SipSmartER
Description: Kids SIPsmartER is grounded by the Theory of Planned Behavior as well as health literacy, media literacy, numeracy, and public health literacy concepts
Study NCT04256941 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Given PO
Study NCT04256941 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abemaciclib
Description: Given PO
Study NCT04256941 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anastrozole
Description: Given PO
Study NCT04256941 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Given IM
Study NCT04256941 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozole
Description: Given PO
Study NCT04256941 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Given PO
Study NCT04256941 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Palbociclib
Description: Given PO
Study NCT04256941 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribociclib
Description: Given PO
Study NCT04256941 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ribociclib
Description: Given PO
Study NCT04115033 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Alpha-stim
Description: The device for both groups is the Alpha-stim, a FDA-approved device similar to the Military Field Stimulator (MFS/Neuro-Stim System), a cranial electrical stimulation (CES) device.
Study NCT00472719 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC-HIVADV027-00-VP
Description: Adenoviral vector booster vaccine
Study NCT00472719 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC-HIVADV038-00-VP
Description: Adenovirus vector booster vaccine
Study NCT03278509 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bisoprolol
Description: Please see the section above.
Study NCT03964441 — intervention group
Intervention type: BIOLOGICAL
Intervention: Invasive fetal sampling, blood sampling of mother and father
Description: to perform an exome sequencing analysis in trio
Study NCT00472719 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC-HIVDNA044-00-VP
Description: Experimental, multiclade, multigene HIV DNA vaccine
Study NCT03964441 — intervention group
Intervention type: BIOLOGICAL
Intervention: blood sampling from the mother to recover the circulating cell free fetal DNA
Description: to perform a sequencing analysis of the genome of circulating free fetal DNA
Study NCT01928173 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Abbreviated cognitive behavioral therapy
Description: see arm description
Study NCT01928173 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sleep education/sleep hygiene
Description: see arm description
Study NCT03948243 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Licorice
Description: Experimental :G. glabra Licorice extract: 2 gelatin capsules (75 mg) per day for 14 days
Study NCT03948243 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alprazolam 2 MG
Description: probe substrate
Study NCT03948243 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caffeine 100 MG
Description: probe substrate
Study NCT03948243 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolbutamide 250 mg
Description: probe substrate
Study NCT03948243 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextromethorphan 30mg
Description: probe substrate
Study NCT01706822 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Covidien Radial Reload Stapler with Tri-Staple Technology
Description: Case series of patients arlaedy selected to undergo a laparoscopic LAR using the Radial Reload stapler
Study NCT05073211 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PDT
Description: A 630 nm red light and a 520 nm green light of the light-emitting diode (LED) device (Nouvo-GB®) with an intensity of 35 mW⁄cm2 was simultaneously illuminated for 10 minutes (a total light dose of 21 J/cm2). Participants received a total of four treatments at 1-week intervals and were followed up 1 and 4 weeks after the last treatment.
Study NCT05073211 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PDT
Description: A 630 nm red light and a 520 nm green light of the light-emitting diode (LED) device (Nouvo-GB®) with an intensity of 35 mW⁄cm2 was simultaneously illuminated for 10 minutes (a total light dose of 21 J/cm2). Participants received a total of four treatments at 1-week intervals and were followed up 1 and 4 weeks after the last treatment.
Study NCT03531359 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TIBD
Description: Table-based Interactive Distraction using video-games will be used to prove efficacy in preventing preoperative anxiety.
Study NCT03531359 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: Administration of midazolam oral or rectal 30 minutes to one hour prior to transfer to the theater.
Study NCT00706693 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Ingestion of BD glucose tablets (TM)
Description: Hypoglycemia (blood glucose is less than 4.0 mmol/L as measured by a glucose meter) will be treated with BD glucose tablets by giving 10g of glucose in children 10 and under. Children and teens over 10 will receive 15g of glucose.
Study NCT00706693 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Ingestion of Skittles (TM)
Description: Hypoglycemia (blood glucose is less than 4.0 mmol/L as measured by a glucose meter) will be treated with Skittle by giving 10g of sucrose in children 10 and under. Children and teens over 10 will receive 15g of sucrose.
Study NCT00706693 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Ingestion of Fruit to Go (TM)
Description: Hypoglycemia (blood glucose is less than 4.0 mmol/L as measured by a glucose meter) will be treated with Fruit to Go by giving 10g of fructose in children 10 and under. Children and teens over 10 will receive 15g of fructose.
Study NCT03904732 — intervention group
Intervention type: DRUG
Intervention: Acetylsalicylic Acid (Aspirin, BAYE4465)
Description: Low-dose acetylsalicylic acid, Aspirin (75-150 mg)
Study NCT00968864 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CliniMACS® (T cell depletion)
Description: Stem cells will be collected from donors after they receive Granulocyte colony-stimulating factor (G-CSF). The cells will be processed using the CliniMACS device to select for CD34+ stem cells and to deplete T cells. Recipients will receive conditioning therapy that is based on their disease type and then receive the CD34+ stem cells.
Study NCT03468101 — intervention group
Intervention type: OTHER
Intervention: Pulmonary Function Testing
Description: Pulmonary Function Testing, Cardiopulmonary exercise testing, 6 Minute walk test, Thoracic CT
Study NCT02407795 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: conventional radiotherapy
Description: 1x8Gy
Study NCT02407795 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: stereotactic radiotherapy
Description: 1x20Gy or equivalent dose fractionation schedule
Study NCT04925726 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Land based exercise
Description: The patients who had land based exercise
Study NCT04925726 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Water based exercise
Description: The patients who had water based exercise
Study NCT03964441 — intervention group
Intervention type: OTHER
Intervention: Parent interviews (optional organizational study)
Description: Interview with a sociologist or psychologist to explore perceptions of ES and the impact of the results, expectations regarding certain types of results not currently available, the emotional situation, and position regarding the continuation of the pregnancy At 4 different times: at inclusion, at the time of the CGA-array results, at the time of the ES results and at a distance from the ES results
Study NCT04767763 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Assessment of TSH, fT3, fT4,TRH, TT3, TT4, rT3 in patients with CVVHDF
Description: blood samples were collected before initiation of CRRT and at 1,2,3,6,9-day following. Last samples were collected 3 days after the end of CRRT.
Study NCT02308189 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise with blood flow restriction
Description: Low load resistance exercise performed with an external pressure cuff applied over both legs or both arms during respective leg and arm exercises.
Study NCT02308189 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Low load resistance exercise performed with no external pressure cuff applied to the appendicular limbs.
Study NCT03822182 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: liposomal bupivicaine
Description: The medication administered in the interscalene block is the intervention in this study. There are three different types of interscalene blocks that will be administered in order to compare the independent effectiveness of LB with the effectiveness of LB plus dexamethasone. Study participants will be randomized into one of three groups. The treatment groups are listed below:~Group 1 (Control): 30 ml of 0.5% bupivacaine and 0.4ml (4 mg) of dexamethasone Group 2: 15ml 0.5% bupivacaine and 10ml (133mg) of LB (Exparel) and 5.4ml normal saline Group 3: 5ml 0.5% bupivacaine and 10ml LB (Exparel) and 0.4ml (4 mg) dexamethasone and 5ml normal saline
Study NCT03822182 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Dexamethasone
Description: steroid that will be used in control as well as in group 3 to see if effect with liposomal bupivicaine is prolonged as has been shown with standard bupivicaine.
Study NCT03822182 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: steroid that will be used in control as well as in group 3 to see if effect with liposomal bupivicaine is prolonged as has been shown with standard bupivicaine.
Study NCT00579878 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leflunomide
Description: A loading dose of 100 mg (or placebo) for three (3) days will be given. Following that three-day period, a dose of 20 mg/day will be maintained throughout the remainder of the study. This dose may be decreased to 10 mg/day at the discretion of the treating physician if minor toxicities occur (e.g., diarrhea, liver enzyme elevations
Study NCT03396835 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: INVSENSOR00009
Description: All subjects who are enrolled into the test group and participate in data collection receive both the INVSENSOR00009 and the control sensor simultaneously on the forehead.
Study NCT02565056 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Self help book + telephone support
Description: Self-help book based upon principles of Acceptance and Commitment Therapy
Study NCT02887261 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: BardPowerPort sip Implantable Port
Description: capable for power injection for contrast media.
Study NCT02887261 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Port
Description: not for power injection for contrast media.
Study NCT00583843 — intervention group
Intervention type: PROCEDURE
Intervention: Ultrasound
Description: Ultrasound weekly during initial fields of radiation, and daily during the boost phase.
Study NCT00882882 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin HCL 500 mg Extended-Release Tablets, Geneva PTC
Study NCT00882882 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GLUCOPHAGE XR 500 mg ER Tablets Bristol-Myers Squibb
Study NCT01672840 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 5g Cocoa Consumption
Description: Daily consumption of 10g Extra Dark cholocate and a beverage containing 2.5g of cocoa powder for 8 weeks
Study NCT03964441 — intervention group
Intervention type: OTHER
Intervention: parent questionnaire (optional organizational study)
Description: To evaluate the experience, perceptions, the impact of the analyses on the decision, satisfaction and concerns regarding the ES and its results, opinions on certain types of results not currently available, as well as anxiety and possible psychological distress At 4 different points in time: at inclusion, at the delivery of the CGA-array results, at the delivery of the ES results and at a distance from the delivery of the ES results
Study NCT03964441 — intervention group
Intervention type: OTHER
Intervention: professional interviews (optional organizational study)
Description: interview to understand how the decision is formed
Study NCT03964441 — intervention group
Intervention type: OTHER
Intervention: Focus group for professionals (optional organizational study)
Description: interview to specify whether variants of unknown significance) VUS will potentially be returned to the clinicians, or even to the patient via the clinician.
Study NCT03321474 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: modified gull wing preparation
Description: preparation is the inciso - proximal extension of porcelain laminates veneer margin more palatally.~The preparation finished at the gingival margin and extended towards the papilla to finish the interproximal elbow preparation.
Study NCT03321474 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: modified gull wing preparation
Description: preparation is the inciso - proximal extension of porcelain laminates veneer margin more palatally.~The preparation finished at the gingival margin and extended towards the papilla to finish the interproximal elbow preparation.
Study NCT01621906 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 18F-FLT-PET Imaging
Description: All patients will be imaged using FLT-PET scans at baseline (within 4 weeks of initiation of WBRT), 7-10 days after completion of WBRT and then 10-12 weeks after WBRT.~Patients will also be evaluated with MRI imaging at baseline and then 10-12 weeks after WBRT.~Patients will be followed with MRI every 3 months (+/- 7 days) for the first year and then every 6 months (+/- 7 days) thereafter which is the standard of care.
Study NCT05085769 — intervention group
Intervention type: PROCEDURE
Intervention: Bariatric surgery
Description: A procedure for morbidly obese patients whose body mass index (BMI) is higher than 40 kg/m2 or 35 kg/m2 and having comorbidities of obesity.
Study NCT01672840 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 10g Cocoa Consumption
Description: Daily consumption of 20g Extra Dark cholocate and two beverage containing 2.5g of cocoa powder each for 8 weeks
Study NCT01276990 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 224436
Description: Oral drinking solution
Study NCT02806687 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gene Therapy product CYL-02
Description: Gene Therapy product CYL 02 = = plasmid DNA encoding SST2 + DCK::UMK genes pre-complexed to linear polyethylenimine.~Intratumoral injection of the gene therapy product CYL-02 (2,5 ml within the primary tumor under endoscopic ultrasound guidance an under propofol anaesthesia). The intratumoral injection of CYL-02 is followed by three IV infusions of Gemcitabine (1000 mg/m2) at 48 hours and then every week. A second Intratumoral injection of the gene therapy product CYL-02 is performed at a same dosage and volume, 30 days after the first administration followed by three infusions of gemcitabine (1000 mg/m2) according the same rhythm (48 hours and every week) and dose. Patients have infusion of Gemcitabine 3 weeks/month during 6 months (or until progression).
Study NCT02806687 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine alone 3 weeks/month during 6 months (or until progression).
Study NCT02806687 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Gemcitabine alone 3 weeks/month during 6 months (or until progression).
Study NCT04546152 — intervention group
Intervention type: DEVICE
Intervention: HYAPROF® SOFT and HYAPROF® BALANCE
Description: Dermal filler injection to different facial areas
Study NCT03600181 — intervention group
Intervention type: DEVICE
Intervention: RAD - 97 pulse co-oximeter
Description: non-invasive sensor capable of measuring ORI (Rainbow® Sensor, R2-25, Revision L, Masimo Corp.) will be applied to the third or fourth finger on the contralateral side of the inflatable cuff for non-invasive blood pressure monitoring.~Values from the RAD 97 monitor will be blinded to clinicians who perform intubation (clinical research nurse will be in charge of watching RAD 97 monitor)
Study NCT02376660 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oats
Study NCT02608840 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Auditory stimulation during sleep
Description: The intervention is a brain computer interface program which measures brain electroencephalogram to identify slow waves and time the sounds. Barely audible sounds are delivered through headphones and played during sleep (specifically, during slow wave sleep).
Study NCT02608840 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Intervention
Description: The brain electroencephalogram is measured and headphones are worn, but sounds are not played during sleep.
Study NCT00603564 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Castar Starmed (CPAP) delivered by a helmet
Description: Continuous Positive Airway Pressure delivered by a helmet with PEEP valve of 10 cmH2O and FiO2 0.5
Study NCT02060045 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bundle implementation
Study NCT00500318 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aclidinium Bromide
Description: Aclidinium Bromide, 200μg. Once daily oral inhalation.
Study NCT00500318 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dose matched placebo, once daily oral inhalation.
Study NCT03609242 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: STOP-HPV bundle intervention
Description: This intervention will be the bundle (training in communication skills, with the addition of performance feedback followed by the addition of provider prompts).
Study NCT03844828 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IOL implantation experimental
Description: Mono- or bilateral implantation of trifocal toric intraocular lenses POD FT. If both eyes of the same patient qualify for the implantation of a trifocal toric lens, a bilateral implantation will be performed. If only one eye qualifies for a trifocal toric lens, the contralateral eye will be implanted with the spherical trifocal IOL POD F (both lenses: (PhysIOL, Liège, Belgium).
Study NCT00625326 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: COL-121
Description: 75 µg/g COL-121 Ointment
Study NCT00625326 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 50 µg/g Calcipotriene Ointment
Description: 50 µg/g Calcipotriene Ointment